290 likes | 407 Views
PRACTICAL REALISATION AND ADVANTAGE OF HAVING A HEART FAILURE CLINIC IN BELGIUM. IS IT POSSIBLE TO REACH « OPTIMAL THERAPY » IN A SPECIALIZED HEART FAILURE CLINIC?. Le Boyer A., Gurné O. Cardiologie Cliniques Universitaires St Luc – UCL Bruxelles. HEART FAILURE CLINIC.
E N D
PRACTICAL REALISATION AND ADVANTAGE OF HAVING A HEART FAILURE CLINIC IN BELGIUM IS IT POSSIBLE TO REACH « OPTIMAL THERAPY » IN A SPECIALIZED HEART FAILURE CLINIC? Le Boyer A., Gurné O. Cardiologie Cliniques Universitaires St Luc – UCL Bruxelles
HEART FAILURE CLINIC An organized system of specialist heart failure care - improves symptoms and reduces hospitalizations Class of recommandation I, Level of evidence A - improves mortality Class of recommandation IIA, Level of evidence B GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE - ESC 2005
Various models have been tested (heart failure clinics, nurse-led home visits,and/or telephone follow-up, multidisciplinary care, extended home care services and telemonitoring,…) It is not clear which model is superior It is likely that the optimal model will depend on local circumstances and resources and whether the model is designed for specific sub-groups of patients GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE - ESC 2005
2006 2007 ? 2003 2006
THE PROBLEM (S) • PAST WAS NOT ALWAYS EASY (PRESENT ?) • Relations between « cardiologists » within the same institution • Relations outside the hospital • Cardiologists working in an hospital or outside • Cardiologist in the University or in Periphery • General practionners and (our) hospital and specialists • PROBLEM OF BUDGET • Could be paradoxal « a priori » … but in Belgium… • « un investissement de départ » THESE PROBLEMS ARE EXITING EVERYWHERE
THE PROBLEM (S) • MIND TO BE CHANGED • DOCTOR = THE ONE who knows (everything) and who does (everything) • patient = the one who is taking the pills without asking any questions • Learn to work in a team • Individualism of the doctors • The patient can – should be an actor of his own health THESE PROBLEMS ARE EXITING EVEYWHERE
Heart Failure Clinic - St Luc Hospital • Hospital based • Nurse led • Mainly taking in charge hospitalized patients in cardiology (EF < 35%) • Education • Coordination • MD (cardiologist, GP • Psychologist • Physiotherapist • Dietician • Nurses of the cardiology unit • Home care (AUXAD : logistical support at home) • Palliative care • Registry • Follow-up of patients (phone calls ><)
Number of CHF patients inclusion extrapolé
Number of CHF patients phone calls extrapolé
INCLUSION • N = 543 patients • Taken from a registry of 1033 patients Ejection fraction < 35%(5 oct 2007) • Patients inclusion was made for this survey according to • Follow-up available at 6 months (or death before) in all patients • No Cardiac surgery or PCI during the 6 first months of follow-up Inclusion data obtained at the end of an hospitalization (for the treatment) Comparison between follow-up • By a specialized structure n = 163 • By another structure (± control group) n = 380
FOLLOW-UP specialized heart failure unit Control Group • Incl/ 6m 163 380 • 12 m 132 80.1 % 230 60.5%
ACE TREATMENT % P=0.10 P=0.06 Specialized CHF clinic Control Group
INH A II TREATMENT % Specialized CHF clinic Control group
ACE or AII INHIBITORS TREATMENT % P=0.02 P=0.02 Specialized CHF clinic Control group
BB TREATMENT % P=0.001 P=0.001 Specialized CHF clinic Control group
ACE /AII INHIBITORS and BB TREATMENT % P=0.001 P=0.001 Specialized CHF clinic Control group
SPIRONOLACTONE TREATMENT % P=0.01 P=0.004 Specialized CHF clinic Control group
ACE /AII INHIBITORS and BB and Spironolactone TREATMENT % P=0.001 P=0.001 Specialized CHF clinic Control group
Relative ACE INH mean daily dose (in % « max dose » Specialized CHF follow-up Control group
Beta Blockers mean daily dose Specialized CHF clinic bisoprolol carvedilol Control group carvedilol bisoprolol
Relative BB mean daily dose (in % « max dose » Specialized CHF follow-up Control group
Combined death or CHF hospitalization events Specialized CHF clinic Controlgroup % % P=0.001 P=0.01
CONCLUSION • In a relatively unselected population, it is posible to reach a high percentage of patients treated by an ACE Inh or an Inh A II AND a Beta Blocker • Higher use of Spironolactone was also achieved • The dosage of these compounds can also be simultaneously more increased, even if the target doses described in the large randomised studies performed were not achieved
CONCLUSION • This approach translate in a better prognosis for these patients • It could explained - partially - the results obtained in « Heart Failure Clinics » • Others factors, such as education and possibility to maintain a closer contact (telephone, consultation) with the patients, play certainly also an important role
ACEI ARB ALDACTONE EPLERENONE